Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study

被引:0
|
作者
Li, Kexuan [1 ]
Zhao, Fuqiang [2 ]
Guo, Yuchen [3 ]
Wu, Qingbin [4 ]
Luo, Shuangling [5 ,6 ,7 ]
Zhang, Junling [8 ]
Li, Heli [9 ]
Hu, Shidong [10 ]
Wu, Bin [1 ]
Lin, Guole [1 ]
Qiu, Huizhong [1 ]
Niu, Beizhan [1 ]
Sun, Xiyu [1 ]
Xu, Lai [1 ]
Lu, Junyang [1 ]
Du, Xiaohui [10 ]
Wang, Zheng [9 ]
Wang, Xin [8 ]
Kang, Liang [5 ,6 ,7 ]
Wang, Ziqiang [4 ]
Wang, Quan [3 ]
Liu, Qian [2 ]
Xiao, Yi [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Div Colorectal Surg, 1 Shuai Fu Yuan Rd, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp,Dept Diagnost Radiol, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China
[3] First Hosp Jilin Univ, Gen Surg Ctr, Dept Gastrointestinal Surg, 1 Xin Min Ave, Changchun 130021, Peoples R China
[4] Sichuan Univ, West China Hosp, Colorectal Canc Ctr, Dept Gen Surg, 37 Guo Xue Xiang, Chengdu 610041, Peoples R China
[5] Sun Yat sen Univ, Affiliated Hosp 6, Dept Gen Surg Colorectal Surg, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[6] Sun Yat sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Dis, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[7] Sun Yat sen Univ, Affiliated Hosp 6, Biomed Innovat Ctr, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[8] Peking Univ First Hosp, Dept Gastrointestinal Surg, 8 Xi Shi Ku St, Beijing 100034, Peoples R China
[9] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, 1277 Jiefang Ave, Wuhan 430022, Peoples R China
[10] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 1, Dept Gen Surg, 28 Fu Xing Rd, Beijing 100853, Peoples R China
基金
中国国家自然科学基金;
关键词
Colon cancer; High-risk pathological features; Adjuvant chemotherapy; PERINEURAL INVASION; PREDICTIVE FACTOR; PROGNOSTIC-FACTOR; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; OUTCOMES; THERAPY; TRIAL;
D O I
10.1186/s12885-023-11196-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We aimed to analyze the benefit of adjuvant chemotherapy in high-risk stage II colon cancer patients and the impact of high-risk factors on the prognostic effect of adjuvant chemotherapy. Methods This study is a multi-center, retrospective study, A total of 931 patients with stage II colon cancer who underwent curative surgery in 8 tertiary hospitals in China between 2016 and 2017 were enrolled in the study. Cox proportional hazard model was used to assess the risk factors of disease-free survival (DFS) and overall survival (OS) and to test the multiplicative interaction of pathological factors and adjuvant chemotherapy (ACT). The additive interaction was presented using the relative excess risk due to interaction (RERI). The Subpopulation Treatment Effect Pattern Plot (STEPP) was utilized to assess the interaction of continuous variables on the ACT effect. Results A total of 931 stage II colon cancer patients were enrolled in this study, the median age was 63 years old (interquartile range: 54-72 years) and 565 (60.7%) patients were male. Younger patients (median age, 58 years vs 65 years; P < 0.001) and patients with the following high-risk features, such as T4 tumors (30.8% vs 7.8%; P < 0.001), grade 3 lesions (36.0% vs 22.7%; P < 0.001), lymphovascular invasion (22.1% vs 6.8%; P < 0.001) and perineural invasion (19.4% vs 13.6%; P = 0.031) were more likely to receive ACT. Patients with perineural invasion showed a worse OS and marginally worse DFS (hazardous ratio [HR] 2.166, 95% confidence interval [CI] 1.282-3.660, P = 0.004; HR 1.583, 95% CI 0.985-2.545, P = 0.058, respectively). Computing the interaction on a multiplicative and additive scale revealed that there was a significant interaction between PNI and ACT in terms of DFS (HR for multiplicative interaction 0.196, p = 0.038; RERI, -1.996; 95%CI, -3.600 to -0.392) and OS (HR for multiplicative interaction 0.112, p = 0.042; RERI, -2.842; 95%CI, -4.959 to -0.725). Conclusions Perineural invasion had prognostic value, and it could also influence the effect of ACT after curative surgery. However, other high-risk features showed no implication of efficacy for ACT in our study.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Survival of Adjuvant Chemotherapy Among Elderly Patients with Stage II Colon Cancer
    Tsai, Tsung-Chih
    Sun, Jia-Ling
    Lin, Wen-Li
    Lee, Sung-Wei
    Chang, Shu-Chan
    Wu, Pei-Hua
    Huang, Wen-Tsung
    Tsao, Chao-Jung
    INTERNATIONAL JOURNAL OF GERONTOLOGY, 2018, 12 (02) : 94 - 99
  • [42] Effect of Adjuvant Chemotherapy on Elderly Stage II High-Risk Colorectal Cancer Patients
    Lee, Yujin
    Park, Inseok
    Cho, Hyunjin
    Gwak, Geumhee
    Yang, Keunho
    Bae, Byung-Noe
    ANNALS OF COLOPROCTOLOGY, 2021, 37 (05) : 298 - 305
  • [43] Patient Selection for Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer A Systematic Review and Meta-Analysis
    Zhang, Chao
    Yin, Songcheng
    Tan, Yuen
    Huang, Jinyu
    Wang, Pengliang
    Hou, Wenbin
    Zhang, Zhe
    Xu, Huimian
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (04): : 279 - 287
  • [44] Utilization and Survival Benefit of Adjuvant Immunotherapy in Resected High-Risk Stage II Melanoma: A National Cancer Database Analysis
    Wong, W. G.
    Olecki, E.
    Stahl, K.
    Holguin, R. Perez
    Pameijer, C.
    Shen, C.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S27 - S27
  • [45] Multi-center evaluation of machine learning-based radiomic model in predicting disease free survival and adjuvant chemotherapy benefit in stage II colorectal cancer patients
    Hui Zhu
    Muni Hu
    Yanru Ma
    Xun Yao
    Xiaozhu Lin
    Menglei Li
    Yue Li
    Zhiyuan Wu
    Debing Shi
    Tong Tong
    Haoyan Chen
    Cancer Imaging, 23
  • [46] Multi-center evaluation of machine learning-based radiomic model in predicting disease free survival and adjuvant chemotherapy benefit in stage II colorectal cancer patients
    Zhu, Hui
    Hu, Muni
    Ma, Yanru
    Yao, Xun
    Lin, Xiaozhu
    Li, Menglei
    Li, Yue
    Wu, Zhiyuan
    Shi, Debing
    Tong, Tong
    Chen, Haoyan
    CANCER IMAGING, 2023, 23 (01)
  • [47] Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute
    Lin, Chun-Chi
    Lin, Jen-Kou
    Chang, Shih-Ching
    Wang, Huann-Sheng
    Yang, Shung-Haur
    Jiang, Jeng-Kai
    Chen, Wei-Shone
    Lin, Tzu-Chen
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2009, 24 (06) : 665 - 676
  • [48] Cost-effectiveness of adjuvant chemotherapy for patients with high-risk stage II and stage III colon cancer in South Africa.
    Pumpalova, Yoanna S.
    Rogers, Alexandra M.
    Tan, Sarah Xinhui
    Herbst, Candice-Lee
    Ruff, Paul
    Neugut, Alfred I.
    Hur, Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute
    Chun-Chi Lin
    Jen-Kou Lin
    Shih-Ching Chang
    Huann-Sheng Wang
    Shung-Haur Yang
    Jeng-Kai Jiang
    Wei-Shone Chen
    Tzu-Chen Lin
    International Journal of Colorectal Disease, 2009, 24 : 665 - 676
  • [50] Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
    Hu, Huabin
    Wu, Zehua
    Wang, Chao
    Huang, Yan
    Zhang, Jianwei
    Cai, Yue
    Xie, Xiaoyu
    Li, Jianxia
    Shen, Cailu
    Li, Weiwei
    Ling, Jiayu
    Xu, Xuehu
    Deng, Yanhong
    FRONTIERS IN ONCOLOGY, 2020, 10